Related Experiment Videos
Prospects for personalized immunosuppression: pharmacologic tools--a review
1Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy. m.deltacca@med.unipi.it
Transplantation Proceedings
|April 28, 2004
Summary
Therapeutic drug monitoring (TDM) is crucial for optimizing immunosuppressive drugs in transplant recipients. Individualizing drug doses based on pharmacokinetics and pharmacogenetics improves efficacy and reduces toxicity.
Area of Science:
- Pharmacology
- Transplantation Medicine
- Clinical Pharmacy
Background:
- Novel immunosuppressive agents have improved transplant outcomes.
- Most immunosuppressants require constant drug level monitoring to prevent rejection and toxicity.
- Factors like genetics, comedications, and comorbidities affect drug pharmacokinetics.
Purpose of the Study:
- To highlight the importance of therapeutic drug monitoring (TDM) in transplant recipients.
- To discuss factors influencing immunosuppressive drug pharmacokinetics.
- To explore the potential role of pharmacogenetics in individualizing immunosuppressive therapy.
Main Methods:
- Review of current literature on immunosuppressive agents and their monitoring.
- Analysis of pharmacokinetic parameters (Cmin, C2) for drug level assessment.
- Exploration of pharmacogenetic studies related to drug targets.
Main Results:
- TDM is essential for optimizing immunosuppression, efficacy, and safety.
- Pharmacokinetic analysis identifies key drug level parameters related to tissue exposure.
- Pharmacogenetic studies are emerging but require further investigation.
Conclusions:
- Individualized dosing based on TDM and pharmacokinetic analysis is critical.
- Pharmacogenetics shows promise for further treatment individualization in transplantation.
- Ongoing research aims to integrate pharmacogenetics into clinical decision-making for immunosuppression.